Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» TD-1473
TD-1473
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Motley Fool
Wed, 02/21/18 - 09:40 am
JNJ
Remicade
TD-1473
Theravance
JAK inhibitors
inflammatory bowel disease
J&J strikes potential $1B JAK inhibitor deal with Theravance
Biopharma Dive
Wed, 02/7/18 - 10:06 am
JNJ
JAK inhibitors
Theravance
TD-1473
drug development
Crohn's Disease
ulcerative colitis